<DOC>
	<DOCNO>NCT01580969</DOCNO>
	<brief_summary>The primary objective step 1 rate adverse event minocycline bevacizumab reirradiation step 2 response rate bevacizumab , reirradiation , minocycline . The secondary objective response rate , PFS-3 , PFS-6 , effect quality life cognition repeat radiation bevacizumab .</brief_summary>
	<brief_title>Repeat Radiation , Minocycline Bevacizumab Patients With Recurrent Glioma</brief_title>
	<detailed_description>After provide informed consent , patient undergo screen eligibility participate study . Screening start within 21 day prior dose . Subjects MRI within 21 day start radiation . QOL cognition measure perform within 21 day start radiation . Radiation give parameter determine individual basis radiation oncologist . Bevacizumab continue 10mg/kg IV every 2 week . Minocycline give twice day start 100mg PO BID . MRI , QOL , cognitive test obtain 1 , 3 6 month end radiation .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>1 . Male female patient ≥18 year old life expectancy least 8 week 2 . Radiographically proven recurrent ( ≥ first relapse ) , intracranial glioma 3 . Previous treatment external beam radiation 4 . Radiographic progression current prior bevacizumab treatment 5 . Women childbearing potential must negative pregnancy test within 7 day initiation dosing must agree use acceptable method birth control study drug 3 month last dose . Women nonchildbearing potential may include either surgically sterile postmenopausal ≥1 year . Men childbearing potential must also agree use acceptable method birth control study drug , 3 month last dose . 6 . Karnofsky performance status ≥50 7 . Adequate hematologic , hepatic , renal function ( absolute neutrophil count ≥1.0 x 109/L , Hgb &gt; 9 g/dL , platelet count ≥50 x 109/L , AST/ALT ≤2.5x ULN , creatinine ≤1.5x ULN ) 8 . Willing able provide write informed consent prior study related procedure comply study requirement 9 . Systolic blood pressure ≤ 160 mg Hg diastolic pressure ≤ 90 mg Hg within 14 day prior study registration 10 . Prothrombin time/international normalize ratio ( PT INR ) &lt; 1.4 patient warfarin confirm test within 14 day prior study registration 11 . Patients fulldose anticoagulant ( e.g. , warfarin LMW heparin ) must active bleed pathological condition carry high risk bleeding , must stable dose oral anticoagulant stable dose low molecular weight heparin 1 . Use investigational drug within 14 day within 5 halflives teh investigational drug , whichever short 2 . Progression within 3 month previous radiation RANO criterion 3 . History Grade 2 ( CTCAE v4 ) great acute intracranial hemorrhage 4 . A concurrent active cancer require nonsurgical therapy ( e.g . chemotherapy , radiation , adjuvant therapy ) . 5 . Patients serious illness , uncontrolled infection , medical condition , medical history include abnormal laboratory result , investigator 's opinion would likely interfere patient 's participation study , interpretation result 6 . Women childbearing potential pregnant breast feed 7 . Unstable angina and/or congestive heart failure last 6 month , transmural myocardial infarction within last 6 month , New York Heart Association grade II higher congestive heart failure require hospitalization within 12 month prior registration , evidence recent myocardial infarction EKG perform within 14 day registration , serious inadequately control cardiac arrhythmia , significant vascular peripheral vascular disease , evidence bleed diathesis coagulopathy 8 . History stroke , cerebral vascular accident ( CVA ) transient ischemic attack within 6 month 9 . Serious nonhealing wound , ulcer , bone fracture history abdominal fistula , gastrointestinal perforation , intraabdominal abscess major surgical procedure , open biopsy , significant traumatic injury within 28 day prior registration , exception craniotomy tumor resection 10 . Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time registration 11 . Active connective tissue disorder , lupus scleroderma , opinion treat physician may put patient high risk radiation toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>glioma</keyword>
</DOC>